BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Miyashita T, Shah FA, Harmon JW, Marti GP, Matsui D, Okamoto K, Makino I, Hayashi H, Oyama K, Nakagawara H, Tajima H, Fujita H, Takamura H, Murakami M, Ninomiya I, Kitagawa H, Fushida S, Fujimura T, Ohta T. Do proton pump inhibitors protect against cancer progression in GERD? Surg Today 2013;43:831-7. [DOI: 10.1007/s00595-012-0395-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Xia Q, Lyu C, Li F, Pang B, Guo X, Ren H, Xing Y, Chen Z. Candidate Drugs Screening for Behcet’s Disease Based on Bioinformatics Analysis and Mouse Experiments. Front Immunol 2022;13:895869. [DOI: 10.3389/fimmu.2022.895869] [Reference Citation Analysis]
2 Darroudi M, Mohammadi Ziarani G, Bahar S, Ghasemi JB, Badiei A. Lansoprazole-Based Colorimetric Chemosensor for Efficient Binding and Sensing of Carbonate Ion: Spectroscopy and DFT Studies. Front Chem 2020;8:626472. [PMID: 33604329 DOI: 10.3389/fchem.2020.626472] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
3 Ward C, Meehan J, Gray ME, Murray AF, Argyle DJ, Kunkler IH, Langdon SP. The impact of tumour pH on cancer progression: strategies for clinical intervention. Exploration of Targeted Anti-tumor Therapy 2020;1:71-100. [DOI: 10.37349/etat.2020.00005] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 4.5] [Reference Citation Analysis]
4 Estrada-Ortiz N, Lopez-Gonzales E, Woods B, Stürup S, de Graaf IAM, Groothuis GMM, Casini A. Ex vivo toxicological evaluation of experimental anticancer gold(i) complexes with lansoprazole-type ligands. Toxicol Res (Camb) 2019;8:885-95. [PMID: 32190293 DOI: 10.1039/c9tx00149b] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
5 Peng YC, Lin CL, Hsu WY, Chow WK, Lee SW, Yeh HZ, Chen CC, Kao CH. Association Between Cholangiocarcinoma and Proton Pump Inhibitors Use: A Nested Case-Control Study. Front Pharmacol 2018;9:718. [PMID: 30018559 DOI: 10.3389/fphar.2018.00718] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
6 Bhardwaj V, Gokulan RC, Horvat A, Yermalitskaya L, Korolkova O, Washington KM, El-Rifai W, Dikalov SI, Zaika AI. Activation of NADPH oxidases leads to DNA damage in esophageal cells. Sci Rep 2017;7:9956. [PMID: 28855537 DOI: 10.1038/s41598-017-09620-4] [Cited by in Crossref: 11] [Cited by in F6Publishing: 16] [Article Influence: 2.2] [Reference Citation Analysis]
7 Hu Q, Sun TT, Hong J, Fang JY, Xiong H, Meltzer SJ. Proton Pump Inhibitors Do Not Reduce the Risk of Esophageal Adenocarcinoma in Patients with Barrett's Esophagus: A Systematic Review and Meta-Analysis. PLoS One 2017;12:e0169691. [PMID: 28072858 DOI: 10.1371/journal.pone.0169691] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 6.8] [Reference Citation Analysis]
8 Song JH, Han Y, Kim WH, Park J, Jeong M, Go EJ, Hong SP, Hahm KB. Oxidative stress from reflux esophagitis to esophageal cancer: the alleviation with antioxidants. Free Radical Research 2016;50:1071-9. [DOI: 10.1080/10715762.2016.1181262] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
9 Neto AG, Whitaker A, Pei Z. Microbiome and potential targets for chemoprevention of esophageal adenocarcinoma. Semin Oncol. 2016;43:86-96. [PMID: 26970127 DOI: 10.1053/j.seminoncol.2015.09.005] [Cited by in Crossref: 18] [Cited by in F6Publishing: 24] [Article Influence: 2.6] [Reference Citation Analysis]
10 Dall'Olmo L, Fassan M, Dassie E, Scarpa M, Realdon S, Cavallin F, Cagol M, Battaglia G, Pizzi M, Guzzardo V, Franceschinis E, Pasut G, Rugge M, Zaninotto G, Realdon N, Castoro C. Role of proton pump inhibitor on esophageal carcinogenesis and pancreatic acinar cell metaplasia development: an experimental in vivo study. PLoS One 2014;9:e112862. [PMID: 25415190 DOI: 10.1371/journal.pone.0112862] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
11 Jin UH, Lee SO, Pfent C, Safe S. The aryl hydrocarbon receptor ligand omeprazole inhibits breast cancer cell invasion and metastasis. BMC Cancer 2014;14:498. [PMID: 25011475 DOI: 10.1186/1471-2407-14-498] [Cited by in Crossref: 71] [Cited by in F6Publishing: 80] [Article Influence: 8.9] [Reference Citation Analysis]
12 O'Sullivan KE, Phelan JJ, O'Hanlon C, Lysaght J, O'Sullivan JN, Reynolds JV. The role of inflammation in cancer of the esophagus. Expert Rev Gastroenterol Hepatol. 2014;8:749-760. [PMID: 24857183 DOI: 10.1586/17474124.2014.913478] [Cited by in Crossref: 31] [Cited by in F6Publishing: 37] [Article Influence: 3.9] [Reference Citation Analysis]